Pharma BD Deal Intelligence

GlaxoSmithKline plc / Theravance, Inc.

2012 · Licensing/Option · $213M · Complete

Announcement Sentiment

Strongly positive

GSK equity investment to acquire 10M Theravance shares at $21.2887 (7.5% premium to 5-day VWAP) for $212.9M, raising stake from 18.3% to ~26.8%. Reinforced respiratory alliance covering Relovair, UMEC/VI, and triple-combination products.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Mar 31, 2012
Closed May 15, 2012
Deal value $213M
Deal type Licensing/Option
Therapeutic area COPD, asthma
Indications COPD, asthma
Key assets FF/UMEC/VI respiratory portfolio (Breo, Anoro, Trelegy precursors)
Mechanism ICS/LAMA/LABA combinations (inhaled)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals